Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 3/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
| ▸ | JAK2 | O60674 | 3/20 | 0.34 |
| ▸ | JAK1 | P23458 | 3/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22264365 | 0.92 | TBK1 (0.39) | LRRK2GRM4JAK2JAK1JAK3 | |
| SCHEMBL25302241 | 0.81 | ACACB (0.39) | LRRK2GRM4ACACBMKNK2GRM5 | |
| SCHEMBL29848596 | 0.81 | ACACB (0.39) | LRRK2GRM4ACACBMKNK2GRM5 | |
| SCHEMBL25258670 | 0.81 | ACACB (0.39) | LRRK2GRM4ACACBMKNK2GRM5 | |
| SCHEMBL4904462 | 0.80 | PRKCZ (0.41) | LRRK2GRM4BRD4GRM5AKT1 | |
| SCHEMBL4904458 | 0.80 | PRKCZ (0.41) | LRRK2GRM4BRD4GRM5AKT1 | |
| SCHEMBL2320140 | 0.75 | MKNK2 (0.47) | LRRK2ACACBMKNK2GRM5 | |
| SCHEMBL30211008 | 0.75 | MKNK2 (0.47) | LRRK2ACACBMKNK2GRM5 | |
| SCHEMBL2320138 | 0.75 | MKNK2 (0.47) | LRRK2ACACBMKNK2GRM5 | |
| SCHEMBL22264282 | 0.74 | MAP3K12 (0.41) | LRRK2GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208412-B2 | Pyrrolo-pyrimidine derivative compound, preparation method therefor, and pharmaceutical composition comprising same compound as effective ingredient for preventing or treating protein kinase-related disease | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2021-12-28 | — | — | US | disclosed |
| US-20200239474-A1 | PYRROLO-PYRIMIDINE DERIVATIVE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME COMPOUND AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208412-B2 | Pyrrolo-pyrimidine derivative compound, preparation method therefor, and pharmaceutical composition comprising same compound as effective ingredient for preventing or treating protein kinase-related disease | LRRK2, WEE1, WEE2 | LRRK2 1/4885GRM4 3020/4885ACACB 3063/4885 |
| US-20200239474-A1 | PYRROLO-PYRIMIDINE DERIVATIVE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME COMPOUND AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE | LRRK2, WEE1, WEE2 | LRRK2 1/4885GRM4 3020/4885ACACB 3063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.